Latest Development Pipeline News

HMC Capital has forged a strategic partnership with global investor KKR, securing up to $603 million to expand its Energy Transition Platform focused on battery storage and wind projects. This deal aims to boost Australia’s renewable capacity while enhancing shareholder returns.

Great Divide Mining has raised $2.5 million through a share placement to fund development at its Challenger Gold Mine and progress other key projects.

Everlast Minerals has secured a significant new exploration licence in northern Bangladesh, boosting its mineral sands portfolio and advancing its development strategy.

Delorean Corporation has completed the $53 million Yarra Valley Water bioenergy facility and progressed key projects in South Australia and Victoria, supported by strong government grants and renewable gas policies.

Biotron Limited has successfully closed its fully subscribed rights issue, raising $1.52 million, and completed the acquisition of Sedarex Limited, positioning itself for growth in its diversified biotech portfolio.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Lunnon Metals has secured unconditional status for its Ore Purchase Agreement with Gold Fields and approved mining at Lady Herial, backed by a robust feasibility study projecting strong cash flows. Exploration continues aggressively across its gold and nickel projects in Western Australia.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Brazilian Rare Earths Limited (BRE) reports a robust scoping study for its Amargosa Bauxite-Gallium Project, alongside a strategic heavy rare earths partnership and a strong cash position to accelerate development.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.